Efforts to expand influenza vaccination programs face a significant hurdle in terms of financial challenges and the need for investment. This poses a particular obstacle for ministries of health and governments of countries that strive for excellence in this area. To address this, it becomes crucial to present stakeholders with compelling data that demonstrate the return on investment in influenza vaccination. This is where cost-effectiveness models play a vital role. These models estimate the amount of funding required to generate specific health benefits within a program. They treat each vaccine and health intervention equally, providing an encompassing understanding of the return on investment for every dollar allocated to a program. The returns can manifest in either monetary savings or, more commonly, in the prevention of numerous cases for every dollar invested. This analysis enables ministers of finance and other decision-makers to compare the cost-effectiveness and returns on investment of influenza vaccines with alternative interventions such as APV vaccines or infrastructure development projects like bridge construction. By utilizing these data-driven insights, interventions can be evaluated and compared effectively. In our work, we assist countries in collecting the necessary data inputs for these models, including disease burden and vaccine effectiveness, and provide support in analyzing and interpreting this information.